Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001599298-24-000158
Filing Date
2024-10-30
Accepted
2024-10-30 07:33:53
Documents
74
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q smmt-20240930.htm   iXBRL 10-Q 1022839
2 EX-31.1 sum-ex311_20240930xduggan.htm EX-31.1 11820
3 EX-31.2 sum-ex312_20240930xzanganeh.htm EX-31.2 11902
4 EX-31.3 sum-ex313_20240930x10qsoni.htm EX-31.3 11929
5 EX-32.1 sum-ex321_20240930x10q.htm EX-32.1 11130
11 GRAPHIC smmt-20240930_g1.jpg GRAPHIC 18976
12 GRAPHIC smmt-20240930_g2.jpg GRAPHIC 39642
  Complete submission text file 0001599298-24-000158.txt   5907191

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20240930.xsd EX-101.SCH 50479
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT smmt-20240930_cal.xml EX-101.CAL 58204
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20240930_def.xml EX-101.DEF 209425
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20240930_lab.xml EX-101.LAB 483778
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20240930_pre.xml EX-101.PRE 347006
77 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20240930_htm.xml XML 695209
Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36866 | Film No.: 241407459
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)